share_log

Cantor Fitzgerald Upgrades Pacific Biosciences to Overweight, Lowers Price Target to $11

Benzinga ·  Oct 31, 2023 10:37

Cantor Fitzgerald analyst Ross Osborn upgrades Pacific Biosciences (NASDAQ:PACB) from Neutral to Overweight and lowers the price target from $14 to $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment